• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Neoprobe taps pharma vet Pykett as development chief

Neoprobe taps pharma vet Pykett as development chief

November 16, 2010 By MedCity News

MedCity News logo

Neoprobe Corp. (OTC:NEOP) hired a biotechnology and pharmaceuticals industry veteran as its chief development officer.

Mark Pykett, 46, is stepping into the role, which calls for him to assist the company with its product and business development, partnering and investor relations efforts, according to a press release from the Dublin, Ohio-based firm.

Pykett joins Neoprobe at what could be a transformative time for the company. Early next year, it’s planning to file for regulatory approval of its cancer-detecting drug Lymphoseek, a tracing agent that identifies cancerous lymph nodes in patients with breast cancer and melanoma. The company pegs the drug’s market at $450 million.

Pykett said he’d help the company prepare its application and provide additional perspective, based on his experience guiding companies through the Food & Drug Administration’s review process.

“I’ll complement what’s already a strong existing team,” he said.

Neoprobe is also seeking to list its shares on New York Stock Exchange’s AMEX market to make itself more attractive to institutional investors. NEOP shares are listed on NASDAQ’s Over-The-Counter Bulletin Board. Pykett said he’d work with investors and analysts to improve the company’s visibility.

The company also is looking to move ahead with clinical trials of RIGScan, a tracing agent that works by attaching itself to cancerous cells in the body, which can then be identified by a handheld radiation-detection device. RIGScan is likely years away from approval.

One of Pykett’s main responsibilities related to RIGScan will be seeking out a larger partner company to commercialize the technology once the agent gains regulatory approval.

Previously, he founded Massachusetts-based Talaris Advisors, a drug-development consulting firm. He was also COO at Alseres Pharmaceuticals, which develops drugs for central nervous system disorders.

Pykett plans to work out of Boston, but said he’ll spend “substantial” time in Dublin and on the road.

Filed Under: Business/Financial News, Diagnostics, News Well, Oncology, Pharmaceutical Tagged With: Navidea Biopharmaceuticals, Personnel Moves

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy